Advanced Drug Delivery: Technologies, Applications, and Markets, 2nd Ed.

Table of Contents

CHAPTER ONE: Executive Summary

• Background
• Scope and Methodology
• Technology and Market Opportunities
  • Polymers and Biomaterials
  • Oral Drug Delivery Devices
  • Pulmonary Drug Delivery
  • Drug Eluting Stent Technology
  • Percutaneous Drug Delivery Technology
  • Ophthalmic Drug Delivery
  • Colloidal Drug Delivery Technologies
  • Site/Organ Specific Drug Delivery
  • Needle-Free Drug Delivery Technology
• Size and Growth of Market

CHAPTER TWO: Drug Delivery Technologies

• Pharmacodynamics and Drug Delivery
  • Small Organic Molecules
  • Pharmaceutical Proteins
  • Vaccines
  • Genes and Antisense Drugs
• Polymers and Biomaterials
  • Non-Absorbable Polymers
  • Polyamine Analogs
  • Magnapore Polymers
  • Natural Biopolymers
  • Intelligent Polymers
• Oral Drug Delivery Devices
  • Extended-Release Technology
  • Delayed-Release Technology
  • Immediate-Dissolution Technology
• Pulmonary Drug Delivery
  • Drug Eluting Stent Technology
• Percutaneous Drug Delivery Technology
  • Intranasal Delivery
  • Iontophoresis
  • Phonophoresis
  • Electroporation
• Ophthalmic Drug Delivery
• Colloidal Drug Delivery Technologies
• Site/Organ Specific Drug Delivery
• Implantable Drug Delivery Systems
• Needle-Free Drug Delivery Technology
• Microneedle Technology
• Nanobiotechnology

CHAPTER THREE: Drug Delivery Applications and Markets

• Background
  • Cardiovascular Diseases
    • Technology Applications
    • Market Assessment
  • Cancer
    • Technology Applications
    • Market Assessment
  • Central Nervous System (CNS) Applications
    • Technology Applications
    • Market Assessment
  • Diabetes
    • Technology Applications
    • Market Assessment
  • Fertility Control and Womens Health
    • Technology Applications
    • Market Assessment
  • Infectious Diseases
    • Technology Applications
    • Market Assessment
  • Pulmonary Diseases
    • Technology Applications
    • Market Assessment

CHAPTER FOUR: Company Profiles

• Overview
• Abbott Vascular Devices Division of Abbott Laboratories
• Alkermes, Inc.
• Andrx Corporation
• Bioject Medical Technologies
• Biovail Corporation
• Boston Scientific
• Cima Labs Inc., A Cephalon Company
• Cordis Corporation A Johnson & Johnson Company
• CyDex, Inc.
• DelSite Biotechnologies
• Durect Corporation
• Elan Corporation plc
• Enzon Pharmaceuticals, Inc.
• Genzyme General
• Guidant Corporation A Johnson & Johnson Company
• Guilford Pharmaceuticals Inc.
• Medtronic, Inc.
• Nastech Pharmaceutical Company Inc.
• Nektar Therapeutics, Inc.
• Skyepharma plc

CHAPTER FIVE: Conclusions and Strategic Implications

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:

Appendix A: Glossary

Appendix B: List of Companies

List of Exhibits

CHAPTER ONE: Executive Summary

• Table 1-1: Estimated U.S. Market Potential for Delivery-Modified Therapeutics 2004-2014
• Table 1-2: Estimated United States Market Potential for Delivery-Modified Therapeutics by Application Area (Cardiovascular, Cancer, CNS, Diabetes, Womens Health, Infectious Disease, Pulmonary) 2004-2014
• Figure 1-1: Trending in the Estimated United States Market Potential for Delivery-Modified Therapeutics by Therapeutic Area 2004-2014

CHAPTER TWO: Drug Delivery Technologies

• Table 2-1: Key Companies Active in Drug Delivery Technology and Products
• Table 2-2: Commonly Used Polymeric Materials for Controlled Drug Release Systems
• Table 2-3: Key Companies Active in Pulmonary Drug Delivery Technology by Application Area/Type of Participation (Diabetes, Pain, Nicotine, OEM Provider, Co-Developer, Asthma, COPD, Cystic Fibrosis, Endocrinology, Reproductive/Hormones, Sleep Disorders, Growth Hormone Deficiency, Prostate Cancer)
• Table 2-4: Pharmaceutical Candidates for Drug-Eluting Stents
• Table 2-5: Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
• Table 2-6: Phonophoresis/Cortisol Trial Results

Chapter Three: Drug Delivery Applications and Markets

• Table 3-1: Estimated U.S. Market Potential for Delivery Modified Therapeutics by Therapeutic Area (Cardiovascular, Cancer, CNS, Diabetes, Womens Health, Infectious Disease, Pulmonary) 2004-2014
• Figure 3-1: Distribution of the Estimated United States Market Potential for Delivery-Modified Therapeutics by Therapeutic Area: 2004-2014
• Table 3-2: Currently Marketed Drug Delivery Modified Cardiovascular Products (Brand, Generic, Manufacturer, Application)
• Table 3-3: Pharmaceutical Candidates for Drug-Eluting Stents
• Table 3-4: Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
• Figure 3-2: Trending in Historic and Forecast United States Coronary Revascularization Procedures: 1990 - 2014
• Table 3-5: Potential U.S. Market for Drug Delivery-Modified Cardiovascular
• Drugs and Drug-Eluting Stents 2004-2014
• Figure 3-3: Trending in the United States Market for Drug Eluting Stents and Modified Delivery Pharmaceuticals 2004-2014
• Figure 3-4: Trending in the Potential United States Market for Delivery All
• Modified Cardiovascular Drug Delivery Products: 2004-2014
• Table 3-6: Currently Marketed Drug Delivery Modified Cancer Therapy Products
• Table 3-7: Potential U.S. Market for Drug Delivery-Modified Cancer Therapeutics by Type (Cytotoxic, Hormone, Blood Restorative, Pain Management, Infection Control) 2004-2014
• Figure 3-6: Trending in the Potential United States Market for Drug Delivery-Modified Cancer Therapeutics: 2001 - 2010
• Table 3-8: Currently Marketed Drug Delivery Modified CNS Therapy Products
• Table 3-9: Potential United States Market for Drug Delivery-Modified CNS Therapeutics: 2004-2014
• Figure 3-7: Trending in the Potential United States Market for Delivery Modified CNS Therapeutics: 2004-2014
• Table 3-10: Currently Marketed Drug Delivery-Modified Diabetes Therapeutics
• Table 3-11: Potential U.S. Market for Drug Delivery-Modified Diabetes
• Therapeutics by Type (Insulin, Oral Hypoglycemics) 2004-2014
• Figure 3-8: Trending in the Potential United States Market for Delivery
• Modified Diabetes Therapeutics: 2004-2014
• Table 3-12: Currently Marketed Drug Delivery-Modified Fertility and
• Womens Health Products
• Table 3-13: Potential United States Market for Drug Delivery-Modified
• Fertility Control and Womens Health Drugs: 2004-2014
• Figure 3-9: Trending in the Potential United States Market for Delivery-
• Modified Fertility Control and Womens Health Drugs 2004-2014
• Table 3-12: Currently Marketed Drug Delivery-Modified Infectious Disease Drugs
• Table 3-13: Potential United States Market for Drug Delivery-Modified Infectious Disease Therapeutics 2004-2014
• Figure 3-10: Trending in the Potential United States Market for Delivery Modified Infectious Disease Therapeutics: 2004-2014
• Table 3-14: Currently Marketed Drug Delivery-Modified Pulmonary Disease Therapeutics
• Table 3-15: Potential United States Market for Drug Delivery-Modified Pulmonary Disease Therapeutics 2004 - 2014
• Figure 3-11: Trending in the Potential United States Market for Delivery Modified Pulmonary Disease Therapeutics 2004-2014